doi:https://doi.org/

The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Journal: Evidence-based Cardiology. 2012;(4): 20‑22

Read: 745 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

. Evidence-based Cardiology. 2012;(4):20‑22. (In Russ.)

Использование инфографики авторами научных работ

References:

Barter P.J., Caulfield M., Eriksson M., et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-2122.
Luscher T.F., Taddei S., Kaski J.C., et al. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur Heart J 2012;33:857-865.
Stein E.A., Stroes E.S., Steiner G., et al. Safety and tolerability of dalcetrapib. Am J Cardiol 2009;104:82-91.
O'Riordan M. dal-OUTCOMES: Wrestling with why the CETP inhibitor failed to reduce outcomes. Available at: www.theheart.org/article/1470569.do.
Boden W.E., Probstfield J.L, Anderson T., et al. Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. N Engl J Med 2011;365:2255-2267.

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.